

EDITORIALS

- 787 Missing clinical trial data: setting the record straight**
Urgent action is needed to restore the integrity of the medical evidence base, say Fiona Godlee and Elizabeth Loder
[» Research, p 816](#) [» Analysis, pp 809, 811](#)
- 788 Apgar score and risk of cerebral palsy**
Low scores are strongly associated with cerebral palsy and its subtypes, says Nigel Paneth
[» Research, p 817](#)
- 789 Variation in caesarean delivery rates**
Specific risk groups should be monitored at a local level, say Marian Knight and Elizabeth A Sullivan
[» Research, p 818](#)
- 790 Are measures of patient satisfaction hopelessly flawed?**
No, but they need further refinement, says Jeannie L Haggerty
[» Research, p 820](#)
- 791 Misleading communication of risk**
Editors should enforce transparent reporting in abstracts, say Gerd Gigerenzer and colleagues

LETTERS

- 793 White matter hyperintensities; Antipsychotics and venous thrombosis**
- 794 Non-commercial clinical trials; Research governance; Electronic health records**

NEWS

- 795 Medical student debt could rise to £70 000**
Summary care records to be scaled back
- 796 NICE decision on dementia drugs was based on "common sense" not evidence, expert says**
Demand for crack addiction treatment drops
- 797 NHS reforms could lead to worse patient care**
Why don't scientists have the same visa exemptions as footballers, ask Nobel winners
- 798 GMC imposes conditions on surgeon's registration after the death of two babies**
Experts criticise proposed German law for favouring drug companies
- 799 Boehringer Ingelheim halts further development of its libido drug for women**
Online sale of drugs needs better regulation, says Nuffield report
- 800 Doctor who spoke out about Darfur atrocities wins award**
New US institute for outcomes research officially starts work
First patient enters trial to test stem cells in spinal injury
- 801 Patients won't get reimbursed for care abroad without prior approval**
Dutch doctors warn that the overuse of antibiotics in farming is increasing resistance

SHORT CUTS

- 802 What's new in the other general journals**

FEATURES

- 804 How can we economise without damaging science?**
As researchers brace themselves for bad news in the spending review, Luisa Dillner argues that cuts will diminish the UK's research pedigree and won't help the economy
- 806 Nominations open for *BMJ* awards 2011**
The *BMJ* Group awards are back for a third year, with three new categories, and more of an international flavour than ever, reports Nigel Hawkes

OBSERVATIONS

BODY POLITIC

- 808 This is no way to cull the quangos**
Nigel Hawkes

ANALYSIS

- 809 Drug studies: a tale of hide and seek**
Beate Wieseler, Natalie McGauran, and Thomas Kaiser use their experience with the assessment of reboxetine to illustrate how publication bias affects health policy decisions and offer some solutions
[» Editorials, p 787](#) [» Research, p 816](#)
- 811 Free the data**
Several recent examples illustrate the problems of trusting drug companies to provide the complete picture about the clinical trials they sponsor. Robert Steinbrook and Jerome P Kassirer propose that investigators and journal editors have full access to data
[» Editorials, p 787](#) [» Research, p 816](#)
- 812 Commentary: Journals must facilitate criticism** Nick Freemantle
- 813 Commentary: Applying the criteria to the RECORD study**
Gordon Coutts
- 814 Commentary: Journals as police officers?**
Chris Del Mar

RESEARCH


- 815 Research highlights: the pick of *BMJ* research papers this week**
- 816 Reboxetine for acute treatment of major depression: systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials**
Dirk Eyding, Monika Lelgemann, Ulrich Grouven, Martin Härter, Mandy Kromp, Thomas Kaiser, Michaela F Kerekes, Martin Gerken, Beate Wieseler
[» Editorial, p 787](#) [» Analysis, p 811](#)



Editorial, p 787, Analysis, pp 809, 811
Missing data: doubting the evidence base




Caesarean deliveries, pp 789, 817



Stem cells for spinal injury, p 800



What the cuts mean for research, p 804



Visa exemptions for scientists too, p 797

- 817 Association of cerebral palsy with Apgar score in low and normal birthweight infants: population based cohort study**
Kari Kveim Lie, Else-Karin Grøholt, Anne Eskild
>> Editorial, p 788
- 818 Variation in rates of caesarean section among English NHS trusts after accounting for maternal and clinical risk: cross sectional study**
Fiona Bragg, David A Cromwell, Leroy C Edozien, Ipek Guroł-Urganci, Tahir A Mahmood, Allan Templeton, Jan H van der Meulen
>> Editorial, p 789
- 819 Reporting of euthanasia in medical practice in Flanders, Belgium: cross sectional analysis of reported and unreported cases**
Tinne Smets, Johan Bilsen, Joachim Cohen, Mette L Rurup, Freddy Mortier, Luc Deliens
- 820 Patients' experience and satisfaction in primary care: secondary analysis using multilevel modelling**
Chris Salisbury, Marc Wallace, Alan A Montgomery
>> Editorial, p 790

CLINICAL REVIEW

- 821 Investigation and management of uveitis**
Catherine M Guly, John V Forrester

PRACTICE

RATIONAL TESTING

- 827 Investigating easy bruising in a child**
Julia A M Anderson, Angela E Thomas

A PATIENT'S JOURNEY

- 830 Through and beyond anaesthesia awareness**
Anne-Marie Aaen, Kirsten Møller

OBITUARIES

- 832 Brian Prichard**
Championed the use of β blockers in hypertension
- 833 Ratan Lal Agrawal; Charlie Granger; Graham Edward Schofield; Rolf Carter Shepherd; Mya Thaug; John K Wagstaff; Alan Edward Wood**

VIEWS AND REVIEWS

PERSONAL VIEW

- 834 GPs should have to take financial responsibility** Danny Ruta

PERSONAL VIEW

- 835 An open letter to the health secretary: how to really save money on the NHS**
Peter Lachmann

REVIEW OF THE WEEK

- 836 The Dreadful and the Divine** Elaine Duigenan

BETWEEN THE LINES

- 837 Hypochondria as control** Theodore Dalrymple

MEDICAL CLASSICS

- 837 Acland's Video Atlas of Human Anatomy** by Robert D Acland
Andy Hall

COLUMNISTS

- 838 Bad medicine: polycystic ovary syndrome**
Des Spence
- There in black and white** Ike Iheanacho

ENDGAMES

- 839 Quiz page for doctors in training**

MINERVA


- 840 Blueberry smoothies, and other stories**



Cerebral palsy and Apgar scores, pp 788, 817



Surgical instruments on show, p 836



How to manage uveitis, p 821

Join your colleagues.

BMJ Masterclasses

masterclasses.bmj.com



16 October 2010 Vol 341

The Editor, BMJBMA House, Tavistock Square,
London WC1H 9JR

Email: editor@bmj.com

Tel: +44 (0)20 7387 4410

Fax: +44 (0)20 7383 6418

BMA MEMBERS' INQUIRIES

Email: membership@bma.org.uk

Tel: +44 (0)20 7383 6642

BMJ CAREERS ADVERTISING

Email: sales@bmjcareers.com

Tel: +44 (0)20 7383 6531

DISPLAY ADVERTISING

Email: sales@bmjgroup.com

Tel: +44 (0)20 7383 6386

REPRINTS

UK/Rest of world

Email: ngurneyrandall@bmjgroup.com

Tel: +44 (0)20 8445 5825

USA

Email: mfogler@medicalreprints.com

Tel: +1 (856) 489 4446

SUBSCRIPTIONS

BMA Members

Email: membership@bma.org.uk

Tel: +44 (0)20 7383 6642

Non-BMA Members

Email: support@bmjgroup.com

Tel: +44 (0)20 7383 6270

OTHER RESOURCES

For all other contacts:

resources.bmj.com/bmj/contact-us

For advice to authors:

resources.bmj.com/bmj/authors

To submit an article:

submit.bmj.com

The BMJ is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the BMJ. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The BMJ follows guidelines on editorial independence produced by the World Association of Medical Editors (www.wame.org/wamestmt.htm#independence) and the code on good publication practice produced by the Committee on Publication Ethics (www.publicationethics.org.uk/guidelines/).

The BMJ is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the BMJ or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2010
All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the BMJ

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to BMJ, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796. Weekly
Printed by Precision Colour Printing Limited



GURINDER OSANI/IPA

PICTURE OF THE WEEK

The R K Khanna Tennis Complex, one of the venues for the 2010 Commonwealth Games, is fumigated at the end of the day to stop the breeding of mosquitoes that have caused an outbreak of dengue fever in New Delhi, India. At least one official has been taken to hospital after contracting the disease, and several athletes have pulled out of the competition.

THE WEEK IN NUMBERS

3 in 10 Proportion of cases of haemophilia in which there is no family history (**Practice**, p 827)

52.8% Reporting rate for euthanasia in Flanders, Belgium, in 2007 (**Research**, p 819)

Up to 115% Percentage by which the benefit of reboxetine was overestimated compared with placebo in published data (**Research**, p 816)

1 in 10 Cases of blindness attributed to uveitis among people of working age in the Western world (**Clinical Research**, p 821)

QUOTE OF THE WEEK

“If left unpruned, quangos would spread like rhododendrons, individually displaying exotic blooms but collectively blighting the scenery”

Nigel Hawkes, freelance journalist, London, on the government spending review

(**Observations**, p 808)

QUESTION OF THE WEEK

Last week's poll asked “Should the NHS mental health services fear the private sector?”

62% said yes (total 189 votes cast)

This week's poll asks “Would a tax on high fat or sugar foods help reduce obesity levels?”

🗳️ **bmj.com** cast your vote

EDITOR'S CHOICE

Evidence debased medicine

Around 4600 people had taken part in trials of reboxetine, yet adequate data on outcomes had been published for only 1600 or so of the participants

Our current evidence base on the benefits and harms of many treatments contains incomplete and questionable evidence. This week Elizabeth Loder and Fiona Godlee call for the record to be set straight and announce a *BMJ* theme issue in late 2011 for research that analyses uncovered evidence (p 787). The aim is to restore trust in the evidence base, not to point fingers.

This is an early call, but such studies take time because they often depend on freedom of information requests and protracted negotiations with companies. Dirk Eyding, Beate Wieseler, and colleagues from the German Institute for Quality and Efficiency in Health Care (IQWiG) show how it's done.

Their health technology assessment of the antidepressant reboxetine began in the usual way last year with an extensive literature search for primary and secondary studies (p 816). They found a yawning gap: around 4600 people had taken part in trials of reboxetine, yet adequate data on outcomes had been published for only 1600 or so of the participants (p 809). Over the next seven months the institute issued its preliminary conclusion that no benefit of reboxetine could therefore be proved; Pfizer (the drug's manufacturer) stated "we provided IQWiG with sufficient data" but then released most of the missing data; and the full assessment showed that, overall, reboxetine had no benefit. At the start, IQWiG had asked the manufacturer to sign an agreement requiring: (1) submission of a list of all sponsored published and unpublished trials investigating reboxetine; (2) submission of documents (generally the clinical study reports) compliant with the CONSORT criteria for all relevant trials selected by IQWiG; and

(3) permission for publication of all previously unpublished relevant data.

Pfizer's provision of the data was an important, if belated, move. We hope that other drug companies and device manufacturers will see the *BMJ*'s theme issue next year as an opportunity to release and use data constructively and to improve clinical decision making. Some have already asked editors' advice on transparency and, despite—or perhaps owing to—the *BMJ*'s reputation for being tough on industry, this journal's editors have recently accepted unpaid invitations to talk with companies about publication ethics. Fiona Godlee and I have visited GlaxoSmithKline and AstraZeneca, and several of us have spoken at industry focused conferences run by organisations including the Drug Information Association and the International Society for Medical Publication Professionals. I have participated, too, in the consultations that produced two sets of guidance for industry based authors: the *Good Publication Practice* guidance (GPP2) (*BMJ* 2009;339:b4330) and the *Authors' Submission Toolkit* (10.1185/03007995.2010.499344).

There's ever more that journals can and should do to improve the evidence base, however. And this week Gerd Gigerenzer and colleagues rightly chastise us for failing to enforce transparent reporting of risks in journal abstracts (p 791). They urge institutions to cancel their subscriptions if we don't implement policies in the next two years to frame risks properly. We have been warned.

Trish Groves, deputy editor, *BMJ* tgroves@bmj.com

Cite this as: *BMJ* 2010;341:c5715

To receive Editor's Choice by email each week, visit bmj.com/cgi/customalert

► Twitter Follow the editor, Fiona Godlee, at twitter.com/fgodlee and the *BMJ*'s latest at twitter.com/bmj_latest



Career Focus, jobs, and courses appear after p 838

Articles appearing in this print journal have already been published on bmj.com, and the version in print may have been shortened. bmj.com also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on bmj.com.

Please cite all articles by year, volume, and locator (rather than page number), eg *BMJ* 2009;338:b145.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.

BMJ.COM: MOST READ

Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee

Low glomerular filtration rate and risk of stroke

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events

Merging of marketing and medical science: female sexual dysfunction

Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality

100% recycled The *BMJ* is printed on 100% recycled paper (except the cover)

